Aug 2026· Frontiers in Microbiology· Vol 17· 0 citations· 29 references
Medicine
TL;DR
The newly characterized phage vB_KpnD_A2 exhibited potent lytic activity against selected multidrug-resistant Klebsiella pneumoniae isolates, favorable genomic safety, and good environmental stability, supporting its potential as a therapeutic phage candidate for CRKP control.
Abstract
Introduction The increasing prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) has posed a major challenge to clinical infection management. Phage therapy represents a promising alternative against multidrug-resistant bacterial infections; however, its application is limited by the scarcity of effective therapeutic phages. Therefore, the identification and characterization of novel phages are urgently needed. Methods A novel Klebsiella pneumoniae phage was isolated and purified from hospital wastewater using the double-layer agar plate method with K. pneumoniae ATCC 700603 as the host strain. A total of 95 bacterial strains were used to evaluate the host range and lytic activity of the phage. The biological characteristics of the phage, including optimal multiplicity of infection (MOI), one-step growth curve, and stability under different environmental conditions (temperature, pH, ethanol, and ultraviolet exposure), were systematically investigated. Morphological characterization was performed by transmission electron microscopy. Whole-genome sequencing and bioinformatics analyses were conducted to determine genomic characteristics, taxonomic classification, and the presence of antibiotic resistance genes, virulence factors, or lysogeny-related genes to assess the therapeutic potential and biosafety of the phage. Results The novel phage vB_KpnD_A2 exhibited potent lytic activity against multidrug-resistant Klebsiella pneumoniae strains. Host range analysis showed that vB_KpnD_A2 lysed 57.1% of carbapenem-resistant K. pneumoniae isolates and 63.6% of extended-spectrum β-lactamase-producing strains, while displaying specificity toward K. pneumoniae. The phage showed excellent biological properties, with an optimal MOI of 10-⁶, a latent period of 40 min, and a burst size of 8.6×10⁴PFU/cell. In addition, vB_KpnD_A2 maintained infectivity over a broad temperature range (4-70°C) and pH range (pH 2-13). Whole-genome analysis identified vB_KpnD_A2 as a strictly lytic Webervirus phage within the family Drexlerviridae, without detectable antibiotic resistance genes, virulence factors, or lysogeny-associated genes, supporting its therapeutic potential and biosafety. Discussion The newly characterized phage vB_KpnD_A2 exhibited potent lytic activity against selected multidrug-resistant Klebsiella pneumoniae isolates, favorable genomic safety, and good environmental stability. These findings support its potential as a therapeutic phage candidate for CRKP control and expand anti-Klebsiella phage resources for future phage-based interventions against antimicrobial-resistant bacterial infections.
BACKGROUND
The global rise of antimicrobial resistance, particularly among carbapenem-resistant Klebsiella pneumoniae (CRKP), presents a serious therapeutic challenge. This study aimed to isolate and characterize a bacteriophage effective against prophage-free CRKP and to evaluate its potential synergistic effects with...
Parva Farmehr, Salehe Sabouri, Roya Ahmadrajabi et al.· Infection & Chemotherapy· 1 citation
Introduction The escalating antimicrobial resistance in Klebsiella pneumoniae underscores the urgent need for alternative therapies. Phage therapy represents a promising approach owing to its specificity, phage self-replication, and potential synergy with antibiotics. Yet, the narrow host range of phages and rapid emer...
Sofia Platova, R. Gorodnichev, A. Shabalina et al.· Frontiers in Microbiology· 0 citations
A collection of candidate phages for further development as potential antimicrobial agents against CR-KP are described and the complexity in understanding phage–host dynamics of phages that recognize non-capsule receptors in K. pneumoniae is described.
D. Mora, Trisha Gryder, L. Lessor et al.· Viruses· 0 citations
The phage merits further study, but whole-genome sequencing, confirmation of the host species, host-range testing against diverse clinical isolates and a controlled comparison with antibiotic treatment are all needed before any therapeutic claim can be made.
M. Sarmykova, A. Abdykalyk, N. Syrym et al.· BioTech· 0 citations
The isolation and characterization of three bacteriophages active against MDR A. baumannii highlight the feasibility of isolating lytic phages from environmental sources and support further investigation of bacteriophage therapy as a complementary strategy to address infections caused by multidrug-resistant pathogens.
Souradeep Chowdhury, N. Rathor, M. Soneja et al.· Le infezioni in medicina· 0 citations
Abstract Klebsiella pneumoniae is a major cause of healthcare-associated and community-acquired infections, increasingly complicated by multidrug resistance (MDR) and carbapenem-resistant K. pneumoniae (CRKp). Phage-based approaches are attractive in such settings but rely on infrastructure and expertise, which are not...
Frank Chilombolwa Nyondo, Bwalya Daka Lalusha, Marriot Chikopa et al.· Access Microbiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.